ArticleClinical rheumatology2026
Exploration of the shared gene signatures and potential molecular mechanisms between Crohn's disease and psoriasis.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Shared inflammatory architecture and therapeutic tensions between psoriasis and Crohn's disease.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveCrohn's disease (CD) and psoriasis are both chronic inflammatory diseases. However, the exact molecular interplay remains incompletely elucidated. This study aimed to identify shared molecular markers and functional pathways underlying both diseases and explore their correlations with immune infiltration.
methodsWe analyzed microarray datasets (GSE30999, GSE186582) from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs). Weighted Gene Co-expression Network Analysis (WGCNA) was used to construct co-expression modules, followed by GO and KEGG enrichment analysis. Hub genes were selected via support vector machine recursive feature elimination (SVM-RFE) and validated in independent datasets (GSE14905, GSE112366). Immune infiltration was evaluated by CIBERSORT.
resultsWe identified 1540 DEGs in CD and 1157 in psoriasis, with 234 overlapping DEGs enriched in the IL-17 signaling pathway (KEGG) and, critically, in secretory granule/cytoplasmic vesicular lumen (GO-CC); these cellular compartments are essential for the production and release of pro-inflammatory cytokines downstream of IL-17 signaling. SVM-RFE identified three hub genes (CLDN8, APOL1, TCN1) validated in independent datasets. In CD, APOL1/TCN1 correlated positively with Neutrophils and inversely with M2 Macrophages, while CLDN8 showed the opposite. In psoriasis, APOL1/TCN1 correlated positively with Activated CD4 Memory T cells and inversely with Resting Mast cells, whereas CLDN8 displayed the opposite.
conclusionThis study elucidated the shared expression markers and functional pathways between CD and psoriasis. These findings offer new clues for comorbid mechanisms and potential therapeutic targets, needing further validation. Key points • The study uncovers shared gene signatures and functional pathways between CD and psoriasis. • Three hub genes (CLDN8, APOL1, TCN1) and IL-17 signaling pathway were validated as potential diagnostic or therapeutic targets for both CD and psoriasis through integrative bioinformatics.
Indexed as
Identifiers
41205134What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.